Close Menu
New York Examiner News

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Are You Under Attack By Howard Bloom

    November 20, 2026

    The Odysseys Blu-ray Is Missing One Major Extra, But Christopher Nolan Has A Good Reason

    November 20, 2026

    The Traitors: New Blood: Jay Vinnedge on Being the King of Chaos & His Supsicions of Katie

    November 20, 2026
    Facebook X (Twitter) Instagram
    New York Examiner News
    • Home
    • US News
    • Politics
    • Business
    • Science
    • Technology
    • Lifestyle
    • Music
    • Television
    • Film
    • Books
    • Contact
      • About
      • Amazon Disclaimer
      • DMCA / Copyrights Disclaimer
      • Terms and Conditions
      • Privacy Policy
    New York Examiner News
    Home»Science»Blocked From Selling Off-Brand Ozempic, Telehealth Startups Embrace a Less Effective Drug
    Science

    Blocked From Selling Off-Brand Ozempic, Telehealth Startups Embrace a Less Effective Drug

    By AdminMay 17, 2025
    Facebook Twitter Pinterest LinkedIn WhatsApp Email Reddit Telegram
    Blocked From Selling Off-Brand Ozempic, Telehealth Startups Embrace a Less Effective Drug

    [ad_1]

    After telehealth startups recently lost the ability to sell exact copies of patented GLP-1 weight-loss drugs, some firms have begun turning to a different, less effective medication that has been on the market in the United States since 2010. Often considered a precursor to blockbuster products like Novo Nordisk’s Ozempic and Eli Lilly’s Zepbound, liraglutide is becoming the new darling of online clinics offering prescription weight loss and diabetes meds—despite its relative old age.

    Originally sold by Novo Nordisk under the brand names Victroza and Saxenda, the drug has been available in generic form in the US since last year. Like Ozempic, liraglutide is a GLP-1 agonist that mimics a naturally occurring hormone and works by suppressing hunger cues and regulating insulin levels. But it doesn’t have the same name recognition or popularity as the newer GLP-1 drugs for a very simple reason: It doesn’t work as well, can cause more severe side effects, and patients have to inject it daily rather than weekly.

    The FDA determined earlier this year that patented medications like Zepound and Ozempic were no longer in shortage, ending provisions that allowed online clinics to sell off-brand, compounded versions of the drugs. As clinics and manufacturers wind down sales of those compounds, many online clinics and manufacturers are embracing liraglutide. Leading telehealth company Hims added generic liraglutide to its lineup last month, joining over a dozen competitors already offering the product in compounded, generic, or name-brand forms.

    Large compounding pharmacies, like Florida-based Olympia Pharmaceuticals, are already pivoting to producing the medication, expecting that demand will rise. “We’ve signed some pretty large contracts for liraglutide,” says chief financial officer Joshua Fritzler. “We can treat it kind of the same way we treated semaglutide and tirzepatide,” the active ingredients in Ozempic and Zepbound. Fritzler says Olympia plans to begin ramping up production this summer.

    GLP-1 medications like Ozempic and Zepbound have been heralded for their unparalleled success in treating obesity and type 2 diabetes. Researchers believe they also have the potential to help patients suffering from a wide variety of other conditions, from addiction to Parkinson’s. After demand for GLP-1s exploded in recent years, the FDA declared that some of the name-brand versions were officially in shortage. That meant doctors could legally prescribe cheaper “compounded” versions of semaglutide and tirzepatide with the same active ingredients as the originals.

    Compounding pharmacies and telehealth startups flourished selling these alternative GLP-1 products online, attracting millions of customers who couldn’t afford or were unwilling to pay higher prices for the name-brand medications, which are frequently not covered by insurance. Now, the shortages for both these meds have ended. The FDA’s grace period for manufacturers to stop producing and selling compounded tirzepatide is over, and the cut-off date for semaglutide is May 22. Liraglutide, though, has been in shortage since April 2023, so the compounders are free to keep making it.

    Some telehealth companies are continuing to offer compounded medications they say aren’t technically direct copies of patented drugs because they come in customized doses or with added vitamins. Eli Lilly has already sued some of them, alleging that these versions are illegal. Other telehealth firms and compounders are playing it safe, ceasing sales altogether. (Olympia, for example, is stopping production of semaglutide.)

    [ad_2]

    Original Source Link

    Share. Facebook Twitter Pinterest LinkedIn WhatsApp Email Reddit Telegram
    Previous ArticleMiroirs No. 3 – first-look review
    Next Article Rhonda Stein Guests On “If These Walls Could Talk” With Hosts Wendy Stuart and Tym Moss Wednesday May 21st, 2025

    RELATED POSTS

    Climate Change Has Pushed the World's Ice Out of Its Safe Zone

    November 12, 2026

    Synchron Pauses Trials of Its Brain Implant Due to Performance Issues

    November 12, 2026

    The Polar Vortex Is About to Make Weather Weird From the UK to the US

    November 12, 2026

    A Startup Wants to Fight AI Bioweapons With AI

    November 11, 2026

    Michigan Residents Voted to Get Corporate Money Out of Politics. Now Utilities Are Suing

    November 11, 2026

    A New Benchmark for De-Aging Comes From Slowly Turning Back Cells Clocks

    November 11, 2026
    latest posts

    Are You Under Attack By Howard Bloom

    This has been a big six weeks for what looks like sabotage. It started with…

    The Odysseys Blu-ray Is Missing One Major Extra, But Christopher Nolan Has A Good Reason

    November 20, 2026

    The Traitors: New Blood: Jay Vinnedge on Being the King of Chaos & His Supsicions of Katie

    November 20, 2026

    Chvrches share tongue-in-cheek new single Evil and announce UK album launch shows in churches

    November 19, 2026

    Fantasy and Science Fiction Books Where the Rules Dont Apply – NewInBooks

    November 19, 2026

    Power Trip Unveil New Song Mutual Death Warrant via GTA 6

    November 19, 2026

    Anthropics IPO puts AIs circular financing boom to the test | TechCrunch

    November 19, 2026
    Categories
    • Books (1,593)
    • Business (6,481)
    • Events (85)
    • Film (6,456)
    • Lifestyle (4,505)
    • Music (6,590)
    • Politics (6,448)
    • Science (5,858)
    • Technology (6,446)
    • Television (6,149)
    • US News (6,491)
    popular posts

    Joe Biden Sets His Sights on Little Girl as Soon as He Arrives in Germany (VIDEO)

    [ad_1] Joe Biden on Saturday traveled to Munich, Germany to meet with G7 leaders and…

    Sequoia backs fintech Dbank in maiden Pakistan investment – TechCrunch

    July 28, 2022

    Hurricane Season Is Soon—NOAA Says It’s Ready, but Weather Experts Are Worried

    May 26, 2025

    Bad Bunny Shares New Song “Una Velita”: Listen

    September 22, 2024
    Archives
    Browse By Category
    • Books (1,593)
    • Business (6,481)
    • Events (85)
    • Film (6,456)
    • Lifestyle (4,505)
    • Music (6,590)
    • Politics (6,448)
    • Science (5,858)
    • Technology (6,446)
    • Television (6,149)
    • US News (6,491)
    About Us

    We are a creativity led international team with a digital soul. Our work is a custom built by the storytellers and strategists with a flair for exploiting the latest advancements in media and technology.

    Most of all, we stand behind our ideas and believe in creativity as the most powerful force in business.

    What makes us Different

    We care. We collaborate. We do great work. And we do it with a smile, because we’re pretty damn excited to do what we do. If you would like details on what else we can do visit out Contact page.

    Our Picks

    Power Trip Unveil New Song Mutual Death Warrant via GTA 6

    November 19, 2026

    Anthropics IPO puts AIs circular financing boom to the test | TechCrunch

    November 19, 2026

    Jax Taylor Reveals Cancer Diagnosis, Has Major Surgery

    November 19, 2026
    © 2026 New York Examiner News. All rights reserved. All articles, images, product names, logos, and brands are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Terms & Conditions and Privacy Policy.

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
    Cookie SettingsAccept All
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
    CookieDurationDescription
    cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
    cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
    cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
    cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
    cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
    viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
    Functional
    Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
    Performance
    Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
    Analytics
    Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
    Advertisement
    Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
    Others
    Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
    SAVE & ACCEPT